4.7 Article

Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain

Journal

EUROPEAN JOURNAL OF NEUROLOGY
Volume 25, Issue 9, Pages 1189-1191

Publisher

WILEY
DOI: 10.1111/ene.13687

Keywords

biomarkers; chitinase 3-like 1; mild cognitive impairment; multiple sclerosis; neurofilament light chain

Funding

  1. Bayer Schering Pharma
  2. Merk Serono
  3. Biogen-Idec
  4. Teva Pharmaceuticals
  5. Genzyme
  6. Novartis
  7. Sanofi-Aventis
  8. Biogen Idec
  9. Bayer
  10. Merck-Serono
  11. Teva Pharmaceutical Industries Ltd
  12. Almirall

Ask authors/readers for more resources

Background and purpose: Chitinase 3-like 1 (CHI3L1) and neurofilament light chain (NF-L) are promising biomarkers of disability in multiple sclerosis (MS). However, their role in cognitive dysfunction remains elusive. Here, we aimed to correlate cerebrospinal fluid (CSF) levels of CHI3L1 and NF-L with cognitive status in MS. Methods: Fifty one recently diagnosed patients were cognitively evaluated and CSF was collected. Levels of CHI3L1 and NF-L were determined by ELISA. Spearman's partial correlation coefficient was performed. Results: After adjusting cognitive scores by age, anxiety and EDSS, association was detected between CHI3L1 levels and Trail Making Test A (rs = 0.348; p = 0.016) and between NF-L levels and Word List Generation (rs = -0.324; p = 0.025). Conclusion: High levels of CSF CHI3L1 and NF-L are associated with cognitive impairment in the early phases of MS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available